The combined value of those assets on the for-sale list, which include Novartis' U.S. generics dermatology business, could reach $2 billion.

Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.

South Korea's PRP has acquires a 6,000 meter plant that can produce 2 million vials of the generic ingredient used in wrinkle fighter Botox.

A yearlong struggle for control of Chinese vaccine maker Sinovac Biotech has forced the company to suspend manufacturing of its hepatitis A vaccine.

AstraZeneca is back at it again with its asset sales. The company offloaded certain Seroquel rights to Luye Pharma for up to $538 million.

The solid-dose API operation of WuXi had its first visit by FDA inspectors at a new plant in Changzhou, China, and the company says it aced it.

Merck's Gardasil rollout in China helped the vaccine franchise grow sales 24% in the first quarter.

India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.

Teva said that while it doesn’t expect a sign-off for the drug by mid-June, it does foresee getting approval for a launch by the end of 2018.